Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | EVP & Chairman, Partnering | September 22, 2026 | September 24, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | March 05, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
Royalty Pharma plc
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy SCH Investment Partners LLC | 274,328 |
Reported balance
After 2026-09-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-22 · Sale · Disposed 96,073 · Balance 274,328 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | IndirectBy SCH Investment Partners LLC | 270,401 |
Reported balance
After 2026-09-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-22 · Sale · Disposed 3,927 · Balance 270,401 F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 23,200 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 23,200 |
Filing footnotes · ownership attribution and instrument terms
F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Vera Therapeutics, Inc.
Report date March 05, 2026 · Filed March 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.85 · Expires 2036-03-04 | Direct | 24,937 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 24,937 · Balance 24,937 F1: The shares subject to the option will vest monthly over a three-year period, subject to the Reporting Person's continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over a three-year period, subject to the Reporting Person's continuous service on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 930 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $92.09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 10,267 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 1,848 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 24, 2026 20:10 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 3,927 | $58.93 | $231,402.79 |
DisclosureSEC source: 0001814238-26-000017 · wk-form4_1790280647.xml · nonDerivative · entry 2 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 270,401 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.88 to $59.00 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:10 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 96,073 | $58.51 | $5,621,692.38 |
DisclosureSEC source: 0001814238-26-000017 · wk-form4_1790280647.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 274,328 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2026 Filed Aug 19, 2026 20:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | GiftClass A Ordinary Shares | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001814238-26-000015 · wk-form4_1787170851.xml · nonDerivative · entry 2 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,200 F3 · kind: The Reporting Person made a charitable gift of Class A Ordinary Shares to Lehigh University. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 20:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 100,000 | $59.97 | $5,997,250.00 |
DisclosureSEC source: 0001814238-26-000015 · wk-form4_1787170851.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 370,401 F1 · kind: All reported sales were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.68 to $60.42 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 11,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001814238-26-000013 · wk-form4_1786137144.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 470,401 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 600 | $57.09 | $34,254.00 |
DisclosureSEC source: 0001814238-26-000011 · wk-form4_1783022904.xml · nonDerivative · entry 4 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.03 to $57.11 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 29,400 | $56.44 | $1,659,403.62 |
DisclosureSEC source: 0001814238-26-000011 · wk-form4_1783022904.xml · nonDerivative · entry 3 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,600 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $56.95 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 2,554 | $57.10 | $145,841.32 |
DisclosureSEC source: 0001814238-26-000011 · wk-form4_1783022904.xml · nonDerivative · entry 2 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 459,399 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.06 to $57.22 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 97,446 | $56.50 | $5,505,971.85 |
DisclosureSEC source: 0001814238-26-000011 · wk-form4_1783022904.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 461,953 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $57.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 117,592 | $54.47 | $6,405,777.16 |
DisclosureSEC source: 0001814238-26-000009 · wk-form4_1782421910.xml · nonDerivative · entry 2 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 559,399 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $54.94 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 21:11 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleClass A Ordinary Shares | 32,408 | $54.11 | $1,753,499.66 |
DisclosureSEC source: 0001814238-26-000009 · wk-form4_1782421910.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Chairman, Partnering 10b5-1 filing: Plan reported Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 676,991 F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.39 to $54.38 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 8, 2026 21:12 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 24,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001814238-26-000007 · wk-form4_1778274737.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 709,399 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:05 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 38,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164226 · ownership.xml · derivative · entry 1 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:49 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 24,937 | $0.00 Strike: $38.85 | $0.00 |
DisclosureSEC source: 0001814238-26-000005 · form4-03092026_080317.xml · derivative · entry 1 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,937 Underlying: Class A Common Stock · 24,937 shares Expires 2036-03-04 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over a three-year period, subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:02 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 26,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001814238-26-000002 · wk-form4_1771016568.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 685,136 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:18 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 6,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001814238-25-000003 · wk-form4_1762550287.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 658,510 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 3,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000102 · wk-form4_1754686485.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 652,342 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass E Ordinary Shares · Derivative | 1,238,789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000071 · wk-form4_1747774487.xml · derivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1)(2) Disclosed balance after: 1,238,789 Underlying: Class A Ordinary Shares · 1,238,789 shares Expires not disclosed F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto. F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:14 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 48,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000035 · wk-form4_1746825246.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 648,646 F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:16 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000012 · wk-form4_1739916980.xml · derivative · entry 3 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 86,641 Underlying: Class A Ordinary Shares · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:16 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000012 · wk-form4_1739916980.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 600,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. Read SEC document |
| May 13, 2024 Filed May 16, 2024 21:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionLP interests in RPI US Partners 2019, LP · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000023 · wk-form4_1715895759.xml · derivative · entry 2 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 541 Underlying: Class A Ordinary Shares · 300,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F3 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 928,800 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| May 13, 2024 Filed May 16, 2024 21:42 UTC | Royalty Pharma plc RPRX · Entity 3100 | ConversionClass A Ordinary Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000023 · wk-form4_1715895759.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · By SCH Investment Partners LLC Disclosed balance after: 370,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange. F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 928,800 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 14:10 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,848 | Not disclosed Strike: $115.53 | Not disclosed |
DisclosureSEC source: 0001104659-21-142278 · tm2133601-11_4seq1.xml · derivative · entry 3 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,848 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 14:10 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,267 | Not disclosed Strike: $92.09 | Not disclosed |
DisclosureSEC source: 0001104659-21-142278 · tm2133601-11_4seq1.xml · derivative · entry 2 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,267 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 14:10 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | OtherCommon Stock | 930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142278 · tm2133601-11_4seq1.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 23:53 UTC | Royalty Pharma plc RPRX · Entity 3100 | SaleLP interests in RPI US Partners 2019, LP · Derivative | 31,959 | $469.86 Strike: $0.00 | $15,016,223.78 |
DisclosureSEC source: 0000950103-21-004602 · dp148454_4-hite.xml · derivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,541 Underlying: Class A Ordinary Shares · 319,590 shares Expires not disclosed F1 · security: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F1 · kind: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F2 · derivative.exercise_date: These RPI US LP Interests were withheld to cover tax withholding obligations. F2 · derivative.expiration_date: These RPI US LP Interests were withheld to cover tax withholding obligations. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:38 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 1,848 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001108 · edgar.xml · derivative · entry 2 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,848 Underlying: Common Stock · 1,848 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 23:38 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001108 · edgar.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930 Read SEC document |
| June 18, 2020 Filed Jun 24, 2020 01:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | PurchaseClass A Ordinary Shares | 70,000 | $28.00 | $1,960,000.00 |
DisclosureSEC source: 0000950103-20-012252 · dp130800_4-hite.xml · nonDerivative · entry 1 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantICAI Interests · Derivative | 116,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012252 · dp130800_4-hite.xml · derivative · entry 3 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,100 Underlying: Limited Partnership interests in RPI US Partners 2019, LP · 116,100 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F4 · derivative.exercise_date: These ICAI Interests represent a grant of up to 116,100 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. F4 · derivative.expiration_date: These ICAI Interests represent a grant of up to 116,100 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share. F2 · derivative.underlying: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 01:13 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantLP interests in RPI US Partners 2019, LP · Derivative | 62,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950103-20-012252 · dp130800_4-hite.xml · derivative · entry 2 Hite Christopher · CIK 0001814238 · EVP & Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Class A Ordinary Shares · 625,000 shares Expires not disclosed F1 · kind: The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP ("RPI US LP") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020. F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. F3 · derivative.exercise_date: These RPI US LP Interests are subject to one-year vesting, with 100% of the interests vesting on March 22, 2021. F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value. Read SEC document |
| June 04, 2020 Filed Jun 6, 2020 00:32 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 10,267 | $0.00 Strike: $92.09 | $0.00 |
DisclosureSEC source: 0001179110-20-007062 · edgar.xml · derivative · entry 1 Hite Christopher · CIK 0001814238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,267 Underlying: Common Stock · 10,267 shares Expires 2030-06-04 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the first three years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.